Business Segments Intellia Therapeutics, Inc.
Equities
NTLA
US45826J1051
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.49 USD | -2.46% |
|
+2.74% | +50.06% |
| Mar. 06 | Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) | RE |
| Mar. 03 | Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran | CI |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Gene Research and Development | ||||||||||
Development of Gene Editing-Based Therapies | 33.05M | 52.12M | 36.28M | 57.88M | 67.67M | |||||
Total Assets | 1.29B | 1.52B | 1.3B | 1.19B | 842M | |||||
CAPEX | -12.76M | -58.39M | -13.98M | -5.78M | -1.13M | |||||
EBT | -268M | -474M | -481M | -519M | -413M | |||||
D&A | 6.89M | 7.57M | 8.98M | 10.28M | 15.92M | |||||
Operating Income | -268M | -458M | -515M | -534M | -441M | |||||
Net Income | -268M | -474M | -481M | -519M | -413M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 33.05M | 52.12M | 36.28M | 57.88M | 67.67M | |||||
Total Assets | 1.29B | 1.52B | 1.3B | 1.19B | 842M | |||||
D&A | 6.89M | 7.57M | 8.98M | 10.28M | 15.92M | |||||
CAPEX | -12.76M | -58.39M | -13.98M | -5.78M | -1.13M | |||||
Net Income | -268M | -474M | -481M | -519M | -413M | |||||
EBT | -268M | -474M | -481M | -519M | -413M | |||||
Operating Income | -268M | -458M | -515M | -534M | -441M |
- Stock Market
- Equities
- NTLA Stock
- Financials Intellia Therapeutics, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
